Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=61 Mindfulness + tDCS to Reduce Urgency Incontinence in Women
Urinary Incontinence, Urge
Primary: Feasibility of Study Procedures Measured by Percentage of Participants Starting Intervention Who Complete the Study — 100; 90.4; 100 percentage of participants who…
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
N/A N=64 Enhancing Conservative Treatment for Urge Incontinence
Urinary Incontinence
Primary: Change in Incontinent Episodes Immediately Post-treatment — -88.5; -78.3 percentage change — p=.16
Phase 4 N=20 Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Urinary Incontinence · Urgency Urinary
Primary: Inflammatory Markers in Urine Will be Measured Using Immunoenzyme Assays to Measure the Interaction of Anticholinergic Treatment and the Inflammatory Milieu. — 2.192…
Phase 4 N=645 Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Frequency of Urge Urinary Incontinence Episodes at Week 12. — -2.5; -1.8 episodes — p=<0.001
N/A N=21 Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Urinary Urge Incontinence
Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016
Phase 3 N=87 An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence
Urinary Incontinence
Primary: Number of Leaks Per Day — NA; NA Number of Leaks Per Day
Phase 3 N=61 Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)
Urge Urinary Incontinence
Primary: Percentage With Treatment Success — 74.1; 75.0 percentage of participants — p=1.0
Phase 4 N=168 Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
Urgency Urinary Incontinence
Primary: Responder (Yes/no) — 23; 39; 36; 17 Participants
N/A N=163 Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder
Overactive Bladder
Primary: Evaluate Proportion of Responders Based on the Change From Baseline in Mean Urgency (Urinary) Incontinence Episodes (Leaks) Between the Active and Sham Treatment Groups…
N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Phase 2 N=80 URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
Overactive Bladder With Urge Urinary Incontinence
Primary: Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes — -1.13; -2.43; -3.37 Urgency episodes per day — p==0.1722
N/A N=74 Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)
Overactive Bladder
Primary: Change in Mean Daily Urgency Incontinence Episodes — -2.5; -2.5 number of incontinence episodes/24 hours
Phase 4 N=42 Validation of a Real-time Urodynamic Measure of Urinary Urgency
Overactive Bladder Syndrome
Primary: Change in Maximal Cystometric Capacity (mL) — 95; 473.50 milliliters (mL) — p=.005
N/A N=82 Efficacy of Surface Electrical Stimulation for Urge Urinary Incontinence in Women
Urge Incontinence
Primary: Change in Average Number of Urinary Incontinence Episodes Per Day — 69.6; 66.1 percentage change — p=<0.0001
N/A N=18 Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
Overactive Bladder
Primary: Change in Urge Incontinence Episodes — 3.9 UUI
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
Phase 4 N=54 Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Overactive Bladder
Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…
N/A N=152 Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy
Urinary Incontinence, Urge
Primary: Percent Change in Urgency Urinary Incontinence Episodes — 73; 88.6 percentage change in median UUI episodes — p=<.025
N/A N=20 Hypnotherapy for Treatment of Overactive Bladder
Overactive Bladder
Primary: Change in Overactive Bladder Symptoms (Based on OABqSF) — -19; -33.4 units on a scale — p=.07
Phase 3 N=85 An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
Overactive Bladder
Primary: Average Number of Voids Per Day — NA; NA Average Number of Voids
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
Phase 4 N=138 Incontinence & Intimate Partners: Assessing the Contribution of Treatment
Urge Urinary Incontinence
Primary: Baseline Sexual Satisfaction Between Matched Female and Male Partners — 4.2; 4.8 score on a scale — p=.16
N/A N=123 Mobile App-treatment of Mixed and Urgency Urinary Incontinence in Women
Urinary Incontinence
Primary: International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) — 7.0; 9.8 score on a scale — p=0.001
Phase 2 N=94 Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence
Urinary Incontinence
Primary: Percentage of Participants With a Decrease in Leakage Events of 30% or More. — 60.6; 61.7 Percentage of participants — p=.92
N/A N=36 A Randomized Controlled Trial of the Uresta Continence Pessary
Stress Urinary Incontinence
Primary: A 50% Reduction in Pad Test Weight — 12; 4 Participants
N/A N=31 A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence
Urinary Incontinence
Primary: Incontinent Episodes Per Day — 7.34; 3.90 incontinence episodes per day — p=<0.01
Phase 3 N=626 Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
Urge Urinary Incontinence · Urinary Frequency
Primary: Change From Baseline in Mean Weekly Frequency of Urinary Incontinence Episodes at Week 12 — -24.8; -21.9; -20.0 Episodes
N/A N=56 Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
Urethral Sphincter Activity
Primary: Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG — -18; 10; 11; -15 microvolts — p=>0.05